1887

Abstract

Oncolytic virotherapy is a unique cancer therapeutic that encompasses tumour cell lysis through both virus replication and programmed cell death (PCD) pathways. Nonetheless, clinical efficacy is relatively modest, likely related to the immunosuppressive tumour milieu. Our studies use the herpes simplex virus type 2 (HSV-2)-based oncolytic virus ΔPK that has documented anti-tumour activity associated with virus replication, PCD and cancer stem cell lysis. They are designed to examine whether ΔPK-mediated oncolysis includes the ability to reverse the immunosuppressive tumour microenvironment by altering the balance of cytokines directly secreted by the melanoma cells and to define its mechanism. Here, we show that melanoma cells secreted the immunosuppressive cytokine IL-10, and that secretion was inhibited by ΔPK through virus replication and c-Jun N-terminal kinase/c-Jun activation. ΔPK-induced IL-10 inhibition upregulated surface expression of MHC class I chain-related protein A, the ligand for the activating NKG2D receptor expressed on NK- and cytotoxic T-cells. Concomitantly, ΔPK also upregulated the secretion of inflammatory cytokines TNF-α, granulocyte macrophage colony-stimulating factor and IL-1β through autophagy-mediated activation of Toll-like receptor 2 pathways and pyroptosis, and it inhibited the expression of the negative immune checkpoint regulator cytotoxic T-lymphocyte antigen 4. Pharmacologic inhibition of these processes significantly reduces the oncolytic activity of ΔPK.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000353
2016-02-01
2020-04-05
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/2/496.html?itemId=/content/journal/jgv/10.1099/jgv.0.000353&mimeType=html&fmt=ahah

References

  1. Akira S., Takeda K., Kaisho T.. 2001; Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol2:675–680 [CrossRef][PubMed]
    [Google Scholar]
  2. Angel P., Karin M.. 1991; The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta1072:129–157[PubMed]
    [Google Scholar]
  3. Aravalli R. N., Hu S., Rowen T. N., Palmquist J. M., Lokensgard J. R.. 2005; Cutting edge: TLR2-mediated proinflammatory cytokine and chemokine production by microglial cells in response to herpes simplex virus. J Immunol175:4189–4193 [CrossRef][PubMed]
    [Google Scholar]
  4. Armeanu S., Bitzer M., Lauer U. M., Venturelli S., Pathil A., Krusch M., Kaiser S., Jobst J., Smirnow I., other authors. 2005; Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res65:6321–6329 [CrossRef][PubMed]
    [Google Scholar]
  5. Aurelian L.. 2004; Herpes simplex virus type 2 vaccines: new ground for optimism?. Clin Diagn Lab Immunol11:437–445[PubMed]
    [Google Scholar]
  6. Aurelian L.. 2013; Oncolytic virotherapy: the questions and the promise. Oncolytic Virother2013:19–29 [CrossRef]
    [Google Scholar]
  7. Bauer S., Groh V., Wu J., Steinle A., Phillips J. H., Lanier L. L., Spies T.. 1999; Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science285:727–729 [CrossRef][PubMed]
    [Google Scholar]
  8. Ben-Sasson S. Z., Hu-Li J., Quiel J., Cauchetaux S., Ratner M., Shapira I., Dinarello C. A., Paul W. E.. 2009; IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A106:7119–7124 [CrossRef][PubMed]
    [Google Scholar]
  9. Bergsbaken T., Fink S. L., Cookson B. T.. 2009; Pyroptosis: host cell death and inflammation. Nat Rev Microbiol7:99–109 [CrossRef][PubMed]
    [Google Scholar]
  10. Bollino D., Balan I., Aurelian L.. 2015; Valproic acid induces neuronal cell death through a novel calpain-dependent necroptosis pathway. J Neurochem133:174–186 [CrossRef][PubMed]
    [Google Scholar]
  11. Bridle B. W., Stephenson K. B., Boudreau J. E., Koshy S., Kazdhan N., Pullenayegum E., Brunelliere J., Bramson J. L., Lichty B. D., Wan Y.. 2010; Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther18:1430–1439[CrossRef]
    [Google Scholar]
  12. Buelens C., Verhasselt V., De Groote D., Thielemans K., Goldman M., Willems F.. 1997; Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor. Eur J Immunol27:756–762 [CrossRef][PubMed]
    [Google Scholar]
  13. Casanova G., Cancela R., Alonzo L., Benuto R., Magana Mdel. C., Hurley D. R., Fishbein E., Lara C., Gonzalez T., other authors. 2002; A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis70:235–239[PubMed]
    [Google Scholar]
  14. Chang Y. L., Chen T. H., Wu Y. H., Chen G. A., Weng T. H., Tseng P. H., Hsieh S. L., Fu S. L., Lin C. H., other authors. 2014; A novel TLR2-triggered signalling crosstalk synergistically intensifies TNF-mediated IL-6 induction. J Cell Mol Med18:1344–1357 [CrossRef][PubMed]
    [Google Scholar]
  15. Chanteux H., Guisset A. C., Pilette C., Sibille Y.. 2007; LPS induces IL-10 production by human alveolar macrophages via MAPKinases- and Sp1-dependent mechanisms. Respir Res8:71 [CrossRef][PubMed]
    [Google Scholar]
  16. Chen L., Zheng L., He W., Qiu M., Gao L., Liu J., Huang A.. 2014; Cotransfection with IL-10 and TGF-β1 into immature dendritic cells enhances immune tolerance in a rat liver transplantation model. Am J Physiol Gastrointest Liver Physiol306:G575–G581 [CrossRef][PubMed]
    [Google Scholar]
  17. Chiocca E. A., Rabkin S. D.. 2014; Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res2:295–300 [CrossRef][PubMed]
    [Google Scholar]
  18. Chuang S. Y., Yang C. H., Chou C. C., Chiang Y. P., Chuang T. H., Hsu L. C.. 2013; TLR-induced PAI-2 expression suppresses IL-1β processing via increasing autophagy and NLRP3 degradation. Proc Natl Acad Sci U S A110:16079–16084 [CrossRef][PubMed]
    [Google Scholar]
  19. Colunga A. G., Laing J. M., Aurelian L.. 2010; The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Ther17:315–327 [CrossRef][PubMed]
    [Google Scholar]
  20. Colunga A., Bollino D., Schech A., Aurelian L.. 2014; Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔPK oncolytic activity in melanoma. Gene Ther21:371–378 [CrossRef][PubMed]
    [Google Scholar]
  21. Contardi E., Palmisano G. L., Tazzari P. L., Martelli A. M., Fala F., Fabbi M., Kato T., Lucarelli E., Donati D., other authors. 2005; CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer117:538–550[CrossRef]
    [Google Scholar]
  22. Crişan T. O., Plantinga T. S., van de Veerdonk F. L., Farcaş M. F., Stoffels M., Kullberg B. J., van der Meer J. W., Joosten L. A., Netea M. G.. 2011; Inflammasome-independent modulation of cytokine response by autophagy in human cells. PLoS One6:e18666 [CrossRef][PubMed]
    [Google Scholar]
  23. de Aquino M. T., Malhotra A., Mishra M. K., Shanker A.. 2015; Challenges and future perspectives of T cell immunotherapy in cancer. Immunol Lett166:117–133 [CrossRef][PubMed]
    [Google Scholar]
  24. de Waal Malefyt R., Haanen J., Spits H., Roncarolo M. G., te Velde A., Figdor C., Johnson K., Kastelein R., Yssel H., de Vries J. E.. 1991; Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med174:915–924 [CrossRef][PubMed]
    [Google Scholar]
  25. Devaud C., John L. B., Westwood J. A., Darcy P. K., Kershaw M. H.. 2013; Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. OncoImmunology2:e25961 [CrossRef][PubMed]
    [Google Scholar]
  26. Dobreva Z. G., Miteva L. D., Stanilova S. A.. 2009; The inhibition of JNK and p38 MAPKs downregulates IL-10 and differentially affects c-Jun gene expression in human monocytes. Immunopharmacol Immunotoxicol31:195–201 [CrossRef][PubMed]
    [Google Scholar]
  27. Fernandes-Alnemri T., Wu J., Yu J. W., Datta P., Miller B., Jankowski W., Rosenberg S., Zhang J., Alnemri E. S.. 2007; The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ14:1590–1604 [CrossRef][PubMed]
    [Google Scholar]
  28. Guo Z. S., Liu Z., Bartlett D. L.. 2014; Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol4:74 [CrossRef][PubMed]
    [Google Scholar]
  29. Gyotoku T., Ono F., Aurelian L.. 2002; Development of HSV-specific CD4+ Th1 responses and CD8+ cytotoxic T lymphocytes with antiviral activity by vaccination with the HSV-2 mutant ICP10DeltaPK. Vaccine20:2796–2807 [CrossRef][PubMed]
    [Google Scholar]
  30. Han J., Lee J. D., Jiang Y., Li Z., Feng L., Ulevitch R. J.. 1996; Characterization of the structure and function of a novel MAP kinase kinase (MKK6). J Biol Chem271:2886–2891 [CrossRef][PubMed]
    [Google Scholar]
  31. Han Z. Q., Assenberg M., Liu B. L., Wang Y. B., Simpson G., Thomas S., Coffin R. S.. 2007; Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy. J Gene Med9:99–106 [CrossRef][PubMed]
    [Google Scholar]
  32. Harris J.. 2011; Autophagy and cytokines. Cytokine56:140–144 [CrossRef][PubMed]
    [Google Scholar]
  33. Hersey P., Gallagher S.. 2014; Intralesional immunotherapy for melanoma. J Surg Oncol109:320–326 [CrossRef][PubMed]
    [Google Scholar]
  34. Hirvinen M., Rajecki M., Kapanen M., Parviainen S., Rouvinen-Lagerstrom N., Diaconu I., Nokisalmi P., Tenhunen M., Hemminki A., Cerullo V.. 2015; [CrossRef] Immunological effects of a tumor necrosis factor-alpha armed oncolytic adenovirus. Hum Gene Ther
    [Google Scholar]
  35. Hornung V., Latz E.. 2010; Critical functions of priming and lysosomal damage for NLRP3 activation. Eur J Immunol40:620–623 [CrossRef][PubMed]
    [Google Scholar]
  36. Hou H., Zhang Y., Huang Y., Yi Q., Lv L., Zhang T., Chen D., Hao Q., Shi Q.. 2012; Inhibitors of phosphatidylinositol 3′-kinases promote mitotic cell death in HeLa cells. PLoS One7:e35665 [CrossRef][PubMed]
    [Google Scholar]
  37. Inoue H., Tani K.. 2014; Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ21:39–49 [CrossRef][PubMed]
    [Google Scholar]
  38. Johnson K. E., Chikoti L., Chandran B.. 2013; Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes. J Virol87:5005–5018 [CrossRef][PubMed]
    [Google Scholar]
  39. Kaufman H. L., Ruby C. E., Hughes T., Slingluff C. L. Jr. 2014; Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. J Immunother Cancer2:11 [CrossRef][PubMed]
    [Google Scholar]
  40. Kim C., Ho D. H., Suk J. E., You S., Michael S., Kang J., Joong Lee S., Masliah E., Hwang D., other authors. 2013; Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat Commun4:1562 [CrossRef][PubMed]
    [Google Scholar]
  41. Kissner T. L., Ruthel G., Cisney E. D., Ulrich R. G., Fernandez S., Saikh K. U.. 2011; MyD88-dependent pro-inflammatory cytokine response contributes to lethal toxicity of staphylococcal enterotoxin B in mice. Innate Immun17:451–462 [CrossRef][PubMed]
    [Google Scholar]
  42. Lawrence T.. 2009; The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol1:a001651 [CrossRef][PubMed]
    [Google Scholar]
  43. Machida N., Umikawa M., Takei K., Sakima N., Myagmar B. E., Taira K., Uezato H., Ogawa Y., Kariya K.. 2004; Mitogen-activated protein kinase kinase kinase kinase 4 as a putative effector of Rap2 to activate the c-Jun N-terminal kinase. J Biol Chem279:15711–15714 [CrossRef][PubMed]
    [Google Scholar]
  44. Marvel D., Gabrilovich D. I.. 2015; Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest125:3356–3364 [CrossRef][PubMed]
    [Google Scholar]
  45. Moretta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M. C., Biassoni R., Moretta L.. 2001; Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol19:197–223 [CrossRef][PubMed]
    [Google Scholar]
  46. Mortha A., Chudnovskiy A., Hashimoto D., Bogunovic M., Spencer S. P., Belkaid Y., Merad M.. 2014; Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis. Science343:1249288 [CrossRef][PubMed]
    [Google Scholar]
  47. Mouawad R., Sebert M., Michels J., Bloch J., Spano J. P., Khayat D.. 2010; Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol74:27–39 [CrossRef][PubMed]
    [Google Scholar]
  48. Norkina O., Dolganiuc A., Shapiro T., Kodys K., Mandrekar P., Szabo G.. 2007; Acute alcohol activates STAT3, AP-1, and Sp-1 transcription factors via the family of Src kinases to promote IL-10 production in human monocytes. J Leukoc Biol82:752–762 [CrossRef][PubMed]
    [Google Scholar]
  49. Oltmanns U., Issa R., Sukkar M. B., John M., Chung K. F.. 2003; Role of c-jun N-terminal kinase in the induced release of GM-CSF, RANTES and IL-8 from human airway smooth muscle cells. Br J Pharmacol139:1228–1234 [CrossRef][PubMed]
    [Google Scholar]
  50. Parviainen S., Ahonen M., Diaconu I., Kipar A., Siurala M., Vaha-Koskela M., Kanerva A., Cerullo V., Hemminki A.. 2015; GMCSF-armed vaccinia virus induces an antitumor immune response. Int J Cancer136:1065–1072[CrossRef]
    [Google Scholar]
  51. Perkins D., Pereira E. F., Aurelian L.. 2003; The herpes simplex virus type 2 R1 protein kinase (ICP10 PK) functions as a dominant regulator of apoptosis in hippocampal neurons involving activation of the ERK survival pathway and upregulation of the antiapoptotic protein Bag-1. J Virol77:1292–1305 [CrossRef][PubMed]
    [Google Scholar]
  52. Rizvi N. A., Hellmann M. D., Snyder A., Kvistborg P., Makarov V., Havel J. J., Lee W., Yuan J., Wong P., other authors. 2015; Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science348:124–128 [CrossRef][PubMed]
    [Google Scholar]
  53. Rommelfanger D. M., Compte M., Diaz R. M., Ilett E., Alvarez-Vallina L., Thompson J. M., Kottke T. J., Melcher A., Vile R. G.. 2013; The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther21:348–357[CrossRef]
    [Google Scholar]
  54. Seglen P. O., Gordon P. B.. 1982; 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc Natl Acad Sci U S A79:1889–1892 [CrossRef][PubMed]
    [Google Scholar]
  55. Serrano A. E., Menares-Castillo E., Garrido-Tapia M., Ribeiro C. H., Hernández C. J., Mendoza-Naranjo A., Gatica-Andrades M., Valenzuela-Diaz R., Zúñiga R., other authors. 2011; Interleukin 10 decreases MICA expression on melanoma cell surface. Immunol Cell Biol89:447–457 [CrossRef][PubMed]
    [Google Scholar]
  56. Shah K. V., Chien A. J., Yee C., Moon R. T.. 2008; CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol128:2870–2879 [CrossRef][PubMed]
    [Google Scholar]
  57. Skov S., Pedersen M. T., Andresen L., Straten P. T., Woetmann A., Odum N.. 2005; Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res65:11136–11145 [CrossRef][PubMed]
    [Google Scholar]
  58. Smith C. C., Peng T., Kulka M., Aurelian L.. 1998; PK domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) is required for immediate-early gene expression and virus growth. J Virol72:9131–9141[PubMed]
    [Google Scholar]
  59. Smith C. C., Nelson J., Aurelian L., Gober M., Goswami B. B.. 2000; Ras-GAP binding and phosphorylation by herpes simplex virus type 2 RR1 PK (ICP10) and activation of the Ras/MEK/MAPK mitogenic pathway are required for timely onset of virus growth. J Virol74:10417–10429 [CrossRef][PubMed]
    [Google Scholar]
  60. Smith C. C., Lee K. S., Li B., Laing J. M., Hersl J., Shvartsbeyn M., Aurelian L.. 2012; Restored expression of the atypical heat shock protein H11/HspB8 inhibits the growth of genetically diverse melanoma tumors through activation of novel TAK1-dependent death pathways. Cell Death Dis3:e371 [CrossRef][PubMed]
    [Google Scholar]
  61. Sutterwala F. S., Haasken S., Cassel S. L.. 2014; Mechanism of NLRP3 inflammasome activation. Ann N Y Acad Sci1319:82–95 [CrossRef][PubMed]
    [Google Scholar]
  62. Teft W. A., Kirchhof M. G., Madrenas J.. 2006; A molecular perspective of CTLA-4 function. Annu Rev Immunol24:65–97 [CrossRef][PubMed]
    [Google Scholar]
  63. Thorne S. H.. 2011; Immunotherapeutic potential of oncolytic vaccinia virus. Immunol Res50:286–293 [CrossRef][PubMed]
    [Google Scholar]
  64. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P. H., Keats J. J., Wang H., Vignali D. A., Bergsagel P. L., Karin M.. 2008; Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat Immunol9:1364–1370 [CrossRef][PubMed]
    [Google Scholar]
  65. Villalba M., Hott M., Martin C., Aguila B., Valdivia S., Quezada C., Zambrano A., Concha M. I., Otth C.. 2012; Herpes simplex virus type 1 induces simultaneous activation of Toll-like receptors 2 and 4 and expression of the endogenous ligand serum amyloid A in astrocytes. Med Microbiol Immunol (Berl)201:371–379 [CrossRef][PubMed]
    [Google Scholar]
  66. Wachsman M., Kulka M., Smith C. C., Aurelian L.. 2001; A growth and latency compromised herpes simplex virus type 2 mutant (ICP10DeltaPK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine19:1879–1890 [CrossRef][PubMed]
    [Google Scholar]
  67. Wales S. Q., Laing J. M., Chen L., Aurelian L.. 2008; ICP10PK inhibits calpain-dependent release of apoptosis-inducing factor and programmed cell death in response to the toxin MPP+. Gene Ther15:1397–1409 [CrossRef][PubMed]
    [Google Scholar]
  68. Wang J. P., Bowen G. N., Zhou S., Cerny A., Zacharia A., Knipe D. M., Finberg R. W., Kurt-Jones E. A.. 2012; Role of specific innate immune responses in herpes simplex virus infection of the central nervous system. J Virol86:2273–2281 [CrossRef][PubMed]
    [Google Scholar]
  69. Whiteside T. L.. 2002; Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol12:43–50 [CrossRef][PubMed]
    [Google Scholar]
  70. Wolf A., Beuerlein K., Eckart C., Weiser H., Dickkopf B., Müller H., Sakurai H., Kracht M.. 2011; Identification and functional characterization of novel phosphorylation sites in TAK1-binding protein (TAB) 1. PLoS One6:e29256 [CrossRef][PubMed]
    [Google Scholar]
  71. Wu Y. T., Tan H. L., Shui G., Bauvy C., Huang Q., Wenk M. R., Ong C. N., Codogno P., Shen H. M.. 2010; Dual role of 3-methyladenine in modulation of autophagy via different temporal patterns of inhibition on class I and III phosphoinositide 3-kinase. J Biol Chem285:10850–10861 [CrossRef][PubMed]
    [Google Scholar]
  72. Yao X. D., Rosenthal K. L.. 2011; Herpes simplex virus type 2 virion host shutoff protein suppresses innate dsRNA antiviral pathways in human vaginal epithelial cells. J Gen Virol92:1981–1993 [CrossRef][PubMed]
    [Google Scholar]
  73. Zamarin D., Holmgaard R. B., Subudhi S. K., Park J. S., Mansour M., Palese P., Merghoub T., Wolchok J. D., Allison J. P.. 2014; Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med6:226–232
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000353
Loading
/content/journal/jgv/10.1099/jgv.0.000353
Loading

Data & Media loading...

Supplements

Supplementary Data

PDF

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error